| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 25, 2025 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 25, 2025 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - SOLIGENIX, INC. (0000812796) (Issuer)
4 - SOLIGENIX, INC. (0000812796) (Issuer)
4 - SOLIGENIX, INC. (0000812796) (Issuer)
PRINCETON, N.J., Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its "reasonable best efforts" public offering with existing and certain healthcare focused institutional investors for the purchase and sale of 5,555,560 shares of common stock of the Company (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,555,560 shares of common stock at a combined purchase price of $1.35 per share and accompanying warrant (the "Offering"). The warrants w
Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including F
PRINCETON, N.J., Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that Christopher J. Schaber, Ph.D., President and Chief Executive Officer, has been invited to deliver a corporate presentation at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The conference will be held September 8 - 10, 2025 with presentations, one-on-one meetings, and networking. The on-demand presentation will be available Friday, September 5th at 7:00 AM ET. The presentation will be available f
424B4 - SOLIGENIX, INC. (0000812796) (Filer)
EFFECT - SOLIGENIX, INC. (0000812796) (Filer)
S-1 - SOLIGENIX, INC. (0000812796) (Filer)
Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J., Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Tomas J. Philipson, PhD as a Strategic Advisor. Dr. Philipson is considered an expert in United States (U.S.) economic policy, particularly health care policy, and frequently appears on major media outlets, including F
PRINCETON, N.J., Sept. 22, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its 2023 Annual Meeting of Stockholders (the "Annual Meeting") scheduled for and convened on September 21, 2023 has been adjourned for the purpose of soliciting additional votes with respect to the proposals described in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission (the "SEC") on August 7, 2023 (the "Proxy Statement"). As a result of the additional ti
Strengthens regulatory and orphan drug development expertise PRINCETON, N.J., May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Timothy R. Coté, M.D., M.P.H. to its Board of Directors. Dr. Coté is a leading national regulatory expert in orphan drug development. With 23 years of Federal service at the U.S. Food and Drug Administration (FDA), National Institu
ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (NASDAQ:NVA) and Soligenix Inc. (NASDAQ:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nova Minerals: https://www.redchip.com/assets/access/nva_accessSoligenix: https://www.redchip.com/assets/access/sngx_accessChristopher Gerteisen, CEO of Nova Minerals, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Nova Minerals p
ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (NASDAQ:SNGX) and American Resources Corp. (NASDAQ:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessAmerican Resources: https://www.redchip.com/assets/access/arec_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and CEO of Soligenix, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 7, 2024 / RedChip Companies will air interviews with Soligenix, Inc. (NASDAQ:SNGX) and Sharps Technology Inc. (NASDAQ:STSS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 8, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Soligenix: https://www.redchip.com/assets/access/sngx_accessSharps Technology: https://www.redchip.com/assets/access/stss_accessIn an exclusive interview, Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix, appears on the RedChip Small Stocks Big Money™ show on B